Sutro Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sutro Biopharma (STRO).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

2S.Buy

10Buy

1Hold

1Sell

Consensus RatingBuy# Analysts14Avg. Consensus PT$27Upside to Avg. PT+18.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	Citizens	Reni J. Benjamin	PT Cut	Market Outperform	$41→$34
Aug 13, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$60
Jun 11, 2026	Truist Securities	Supawat Thongthip	Assumes	Buy	$50
May 28, 2026	Barclays	Lukas Shumway	Initiate	Overweight	$56
May 15, 2026	Leerink Partners	—	PT Raise	Outperform	$38→$43
May 15, 2026	Wedbush	David Nierengarten	Upgrade	Neutral→Outperform	$22→$60
May 15, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Buy	$28→$50
Apr 30, 2026	Mizuho	Salim Syed	Initiate	Outperform	$50
Apr 23, 2026	Citizens	Reni J. Benjamin	PT Raise	Market Outperform	$35→$41
Apr 17, 2026	Citizens	Reni J. Benjamin	PT Raise	Market Outperform	$23→$35
Apr 7, 2026	Leerink Partners	—	Initiate	Outperform	$38
Mar 25, 2026	Deutsche Bank	James Shin	PT Raise	Buy	$51→$55
Mar 24, 2026	Wells Fargo	Eva Fortea Verdejo	Upgrade	Equal-Weight→Overweight	$8→$27
Mar 24, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Upgrade	Neutral→Buy	$10→$28
Jan 20, 2026	Citizens	Reni Benjamin	Upgrade	Market Perform→Market Outperform	$23
Dec 22, 2025	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Neutral	$2→$10
Aug 12, 2025	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$4→$3
Jun 16, 2025	Piper Sandler	Edward Tenthoff	Upgrade	Neutral→Overweight	$2
May 19, 2025	B of A Securities	Tazeen Ahmad	PT Cut	Underperform	$1→$1
Apr 29, 2025	HC Wainwright & Co.	Andres Maldonado	Maintained	Neutral	$2

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and lowers the price target from $41 to $34.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.

Benzinga Newsdesk

PRO
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

Truist Securities analyst Supawat Thongthip assumes Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $50.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Overweight rating and announces Price Target of $56.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

Leerink Partners maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and raises the price target from $38 to $43.

Benzinga Newsdesk

PRO
Wedbush Upgrades Sutro Biopharma to Outperform, Raises Price Target to $60

Wedbush analyst David Nierengarten upgrades Sutro Biopharma (NASDAQ:STRO) from Neutral to Outperform and raises the price target from $22 to $60.

Benzinga Newsdesk

Sutro Biopharma Inc

Sutro Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

PRO
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

PRO
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

PRO
Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

PRO
Leerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

PRO
Wedbush Upgrades Sutro Biopharma to Outperform, Raises Price Target to $60

People Also Watch

People Also Watch

Benzinga

Benzinga

Sutro Biopharma Inc

Sutro Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

PROWedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

PROTruist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

PROBarclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

PROLeerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

PROWedbush Upgrades Sutro Biopharma to Outperform, Raises Price Target to $60

People Also Watch

People Also Watch

PRO
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

PRO
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

PRO
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

PRO
Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

PRO
Leerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

PRO
Wedbush Upgrades Sutro Biopharma to Outperform, Raises Price Target to $60